The University of Texas MD Anderson Cancer Center CIMAC is a collaborative and multi-disciplinary group with large-scale institutional and national biorepository expertise, including longitudinal collection and “real-time” immune-profiling analysis of samples in immunotherapy trials.

The CIMAC’s access to MD Anderson’s computational and statistical resources includes centralized data banking, advanced statistical pipelines for multi-platform high-throughput “omics” data integration, and the Translational Research Accelerator (TRA)/Big Data Platform.

MD Anderson logo

Principal investigators

Photo of Ignacio Wistuba, MD

Ignacio Wistuba, MD

Chair and Professor, Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center

Head ad interim, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center

Co-director of the Khalifa Institute of Personalized Cancer Institute at the University of Texas MD Anderson Cancer Center

Dr. Wistuba’s primary research interest is the elucidation of the molecular abnormalities involved in the pathogenesis and progression of lung cancer and other solid tumors. At MD Anderson, he oversees several translational research laboratories and platforms, and is principal investigator on several molecular pathology and biomarker projects supported by multi-investigator and multi-institutional grants, and research agreements. Dr. Wistuba is associate editor of Annals of Oncology (ESMO) and Cancer Prevention Research (AACR).

Photo of Cara Haymaker, PhD

Cara Haymaker, PhD

Assistant Professor, Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center

Dr. Haymaker’s major research interests are understanding the tumor microenvironment of mesothelioma and the role of dendritic cells in multiple solid tumors. As the Director of both the Translational Molecular Pathology-Immunoprofiling lab (TMP-IL) and CCSG developmental ORION core, she is actively involved in immunoprofiling specimens longitudinally collected on clinical trials at MDACC. She is also involved in multiple grant-funded biomarker projects supporting translational research. Dr. Haymaker is an active member of the Society for Immunotherapy of Cancer (SITC) and American Association for Cancer Research (AACR), and participates in the peer-review process of multiple journals as either an associate editor or reviewer.

Photo of Gheath Alatrash, MD, PhD

Gheath Alatrash, MD, PhD

Associate Professor, Department of Stem Cell Transplantation and Cellular Therapy

Medical Director, Evolution of Cancer, Leukemia, and Immunity Post Stem cEll transplant (ECLIPSE) platform, The University of Texas MD Anderson Cancer Center

Dr. Alatrash is a physician-scientist, clinically trained in medical oncology/hematology and scientifically trained in immunology. As a physician, he is board certified in medical oncology and hematology, and is heavily involved in the care of patients who are actively being treated with immunotherapy. His clinical focus is on the treatment of patients with hematologic and solid tumor malignancies using autologous and allogeneic stem cell transplants, as well as adoptive cellular therapies. He leads a number of clinical trials investigating the role of immunotherapy in hematologic and solid tumor malignancies. Scientifically, he focuses on translating laboratory discoveries to the clinical setting, specifically developing novel immunotherapeutic approaches and discovering new antigens that can be effectively targeted in the treatment of cancer.